Abstract
Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. Patients & methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant. Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €353,000 (EU5) and €699,000 (Sweden; 1-month formulations), and €259,000 (EU5) and €300,000 (Sweden; 3-month formulations). Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.
| Original language | English |
|---|---|
| Journal | Journal of Comparative Effectiveness Research |
| Volume | 4 |
| Issue number | 5 |
| Pages (from-to) | 447-453 |
| Number of pages | 7 |
| ISSN | 2042-6305 |
| DOIs | |
| Publication status | Published - 09.2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
Fingerprint
Dive into the research topics of 'Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: A solid biodegradable leuprorelin implant versus other formulations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver